Drug Profile
Research programme: benzopyran therapeutics - Celgene
Alternative Names: CC 02217113; CC 132889Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Benzopyrans
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 09 May 2007 Preclinical development is ongoing